Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Equity Average (2022 - 2025)

Stoke Therapeutics has reported Equity Average over the past 4 years, most recently at $330.3 million for Q4 2025.

  • Quarterly results put Equity Average at $330.3 million for Q4 2025, up 43.25% from a year ago — trailing twelve months through Dec 2025 was $330.3 million (up 43.25% YoY), and the annual figure for FY2025 was $290.7 million, up 49.64%.
  • Equity Average for Q4 2025 was $330.3 million at Stoke Therapeutics, up from $321.5 million in the prior quarter.
  • Over the last five years, Equity Average for STOK hit a ceiling of $342.5 million in Q2 2025 and a floor of $150.0 million in Q1 2024.
  • Median Equity Average over the past 4 years was $214.2 million (2022), compared with a mean of $232.2 million.
  • Biggest five-year swings in Equity Average: dropped 24.77% in 2024 and later surged 93.09% in 2025.
  • Stoke Therapeutics' Equity Average stood at $194.5 million in 2022, then fell by 14.51% to $166.3 million in 2023, then skyrocketed by 38.66% to $230.6 million in 2024, then soared by 43.25% to $330.3 million in 2025.
  • The last three reported values for Equity Average were $330.3 million (Q4 2025), $321.5 million (Q3 2025), and $342.5 million (Q2 2025) per Business Quant data.